Clascoterone as a novel treatment for androgenetic alopecia

The authors propose that clascoterone, a novel androgen receptor inhibitor, may be a promising treatment for androgenetic alopecia. Clascoterone antagonizes dihydrotestosterone (DHT) through competitive binding with cytoplasmic androgen receptors, and DHT is known to play a causal role in the development of androgenetic alopecia. Clascoterone has been found to have the same efficacy as finasteride in vitro and preliminary industry studies demonstrate a hair growth signal comparable with established treatments such as minoxidil. The authors suggest that clascoterone presents a promising therapeutic avenue for this commonly encountered condition.